Clinical Randomisation of an Antifibrinolytic in Significant Head Injury (CRASH-3)
Not Applicable
Recruiting
- Conditions
- Injury, Occupational Diseases, PoisoningNervous System DiseasesTraumatic Brain Injury
- Registration Number
- PACTR201210000441277
- Lead Sponsor
- 1. London School of Hygiene and Tropical Medicine (United Kingdom)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10000
Inclusion Criteria
1. Adult
2. Traumatic brain injury
3. Within 8 hours of injury
4. Any intracranial bleeding on CT scan OR a GCS of 12 or less
5. No significant extra-cranial haemorrhage
6. Where the responsible clinician is substantially uncertain as to the appropriateness of antifibrinolytic agents in the patient
Exclusion Criteria
The fundamental eligibility criterion is the responsible clinician's 'uncertainty' as to whether or not to use an antifibrinolytic agent in a particular patient with traumatic brain injury
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie tranexamic acid's antifibrinolytic effects in traumatic brain injury?
How does tranexamic acid compare to standard-of-care treatments for significant head injury outcomes?
Which biomarkers correlate with improved neurological outcomes in CRASH-3 trial participants?
What are the potential adverse events associated with tranexamic acid in traumatic brain injury patients?
Are there combination therapies involving tranexamic acid that enhance treatment efficacy for traumatic brain injury?